Dynavax Technologies Cash on Hand 2010-2022 | DVAX

Dynavax Technologies cash on hand from 2010 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Dynavax Technologies Annual Cash on Hand
(Millions of US $)
2021 $546
2020 $165
2019 $151
2018 $146
2017 $192
2016 $81
2015 $196
2014 $123
2013 $189
2012 $125
2011 $114
2010 $72
2009 $37
Dynavax Technologies Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $503
2021-12-31 $546
2021-09-30 $414
2021-06-30 $346
2021-03-31 $233
2020-12-31 $165
2020-09-30 $177
2020-06-30 $201
2020-03-31 $130
2019-12-31 $151
2019-09-30 $175
2019-06-30 $140
2019-03-31 $183
2018-12-31 $146
2018-09-30 $180
2018-06-30 $216
2018-03-31 $251
2017-12-31 $192
2017-09-30 $192
2017-06-30 $127
2017-03-31 $85
2016-12-31 $81
2016-09-30 $110
2016-06-30 $139
2016-03-31 $167
2015-12-31 $196
2015-09-30 $221
2015-06-30 $93
2015-03-31 $98
2014-12-31 $123
2014-09-30 $131
2014-06-30 $154
2014-03-31 $178
2013-12-31 $189
2013-09-30 $76
2013-06-30 $89
2013-03-31 $105
2012-12-31 $125
2012-09-30 $148
2012-06-30 $160
2012-03-31 $107
2011-12-31 $114
2011-09-30 $53
2011-06-30 $62
2011-03-31 $53
2010-12-31 $72
2010-09-30 $48
2010-06-30 $58
2010-03-31 $31
2009-12-31 $37
2009-09-30 $47
2009-06-30 $54
2009-03-31 $61
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.637B $0.439B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00